AstraZeneca plans direct New York listing in another blow to UK life sciences

AstraZeneca to switch from Nasdaq ADRs to direct NYSE listing, aims to reach more global investors. Move follows recent UK investment pullbacks & NICE tensions over Enhertu.Read More